Interaction Checker

Add peptides or compounds to check all pairwise interactions, cumulative organ load, and safety flags.

This stack looks good: 1 synergistic interaction(s) found. No conflicts detected.

Cumulative Organ Load

Heart
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Ezetimibe, Rosuvastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Ezetimibe, Rosuvastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Ezetimibe, Rosuvastatin). Monitor accordingly.
++
Ezetimibe + Rosuvastatin
Synergistic

Rosuvastatin and ezetimibe target complementary pathways in cholesterol metabolism -- rosuvastatin inhibits hepatic synthesis while ezetimibe blocks intestinal absorption. The combination (available as the fixed-dose product Roszet) provides an additional 15-20% LDL reduction beyond rosuvastatin alone. Particularly useful for AAS users whose lipids remain elevated despite statin monotherapy, or for those running especially hepatotoxic oral stacks.

Researched 95% confidence Compare

Interaction data is compiled from research literature, pharmacological analysis, and community reports. Inferred interactions are based on known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.